# Effect of Efpeglenatide on Cardiovascular Outcomes

Study · id `cardio:ct-nct03496298` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03496298](<https://clinicaltrials.gov/study/NCT03496298>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03496298

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 4076 participants.

## Technical summary

Registry record NCT03496298. Randomized; quadruple masking; primary purpose treatment. Start 2018-04-27 (actual); primary completion 2020-12-10 (actual). Results posted on 2021-10-15.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 4076 participants (enrolled count; ClinicalTrials.gov record NCT03496298, source copy `cardio:ctgov-nct03496298-2021-10-15`, retrieved 2026-10-26)
- Started: 2018-04-27 (actual) (ClinicalTrials.gov record NCT03496298, source copy `cardio:ctgov-nct03496298-2021-10-15`, retrieved 2026-10-26)
- Primary completion: 2020-12-10 (actual) (ClinicalTrials.gov record NCT03496298, source copy `cardio:ctgov-nct03496298-2021-10-15`, retrieved 2026-10-26)
- Completion: 2020-12-10 (actual) (ClinicalTrials.gov record NCT03496298, source copy `cardio:ctgov-nct03496298-2021-10-15`, retrieved 2026-10-26)
- Results first posted: 2021-10-15 (ClinicalTrials.gov record NCT03496298, source copy `cardio:ctgov-nct03496298-2021-10-15`, retrieved 2026-10-26)
- Countries: United States; Argentina; Bulgaria; Canada; Chile; Denmark; Estonia; Finland; Germany; Hungary; India; Italy; Latvia; Lithuania; Mexico; Norway; Peru; Poland; Romania; Russia; Serbia; Slovakia; South Africa; South Korea; Spain; Sweden; Türkiye; Ukraine (ClinicalTrials.gov record NCT03496298, source copy `cardio:ctgov-nct03496298-2021-10-15`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03496298-2021-10-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effect of Efpeglenatide on Cardiovascular Outcomes
- Acronym: AMPLITUDE-O
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Efpeglenatide (SAR439977)
- Intervention (Drug): Placebo
- Lead sponsor: Sanofi
- Lead sponsor class: INDUSTRY
- Collaborator: Hanmi Pharmaceutical Company Limited
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: Sanofi (`cardio:org-sanofi`)
- Registry lists this organization as a collaborator: Hanmi Pharmaceutical Company Limited (`cardio:org-hanmi-pharmaceutical-company-limited`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes (`cardio:pubmed-34215025`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial (`cardio:pubmed-34775781`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Exploring the Relationship Between Efpeglenatide Dose and Cardiovascular Outcomes in Type 2 Diabetes: Insights From the AMPLITUDE-O Trial (`cardio:pubmed-36802715`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 163607ba9df575dabd5f362763a82e5aae9a709cb9e4da48f1e3c5ad7754fc0f
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
